DSOG Guideline Bulletin: Preeclampsia and hypertension
Main Article Content
Abstract
Approximately 10% of pregnancies are complicated by hypertensive disorders of pregnancy (HDPs) in Denmark. The ‘Preeclampsia and hypertension’ guideline includes the classification, diagnosis, surveillance, and management of HDPs. This revision focuses on the diagnostic criteria for preeclampsia, preeclampsia-specific biomarkers for short-term prediction of disease, blood pressure thresholds and targets, and postpartum management. We reviewed the available literature in PubMed published since the last guideline revision in 2018, as well as the guidelines of other obstetric societies. HDPs are classified based on the timing of onset, i.e. before or after 20 weeks’ gestation, and whether proteinuria or other signs of organ dysfunction are present. We recommend against using the terms mild-moderate or severe preeclampsia in clinical practice. If possible, new-onset hypertension should be confirmed by home blood pressure monitoring. Women with HDPs should be monitored regularly, depending on diagnosis and clinical presentation. If blood pressure is ≥140 mmHg systolic and/or ≥90 mmHg diastolic, antihypertensive treatment with oral labetalol, nifedipine or methyldopa should be offered and titrated until reaching a target blood pressure of <135/85 mmHg. Magnesium sulphate treatment is recommended in eclampsia or signs of impending eclampsia. Delivery should be offered to women with preeclampsia no later than 37-38 weeks’ gestation; delivery is indicated sooner, regardless of gestational age, in preeclampsia with signs of serious, progressive disease which may include uncontrollable blood pressure, eclampsia, pulmonary oedema, progressive deterioration of biochemical parameters, or severe foetal compromise. Before operative delivery, blood pressure should be stable below 150/100 mmHg. Women with chronic or gestational hypertension should be offered planned delivery at 38-40 weeks’ gestation. Antihypertensive treatment should be continued at least one week after delivery. Lifelong yearly blood pressure monitoring is recommended to all women with HDPs.
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
CC BY. The paper and it's contents belong to the author, and can be used by others when giving appropriate credit to the authors and the creator (DJOG).
How to Cite
References
Magee LA, Nicolaides KH, Von Dadelszen P. Preeclampsia. Longo DL, editor. N Engl J Med. 2022 May 12;386(19):1817–32. DOI: https://doi.org/10.1056/NEJMra2109523
OCEBM Levels of Evidence Working Group. “The Oxford Levels of Evidence 2” Oxford Centre for Evidence-Based Medicine. [Internet]. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
DSOG. Hypertension og præeklampsi. 2024 p. 1–48.
Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & man-agement recommendations for international practice. Pregnancy Hypertens. 2022 Mar 1;27:148–69. DOI: https://doi.org/10.1016/j.preghy.2021.09.008
ACOG. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020 Jun;135(6):e237–60. DOI: https://doi.org/10.1097/AOG.0000000000003891
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the man-agement of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018 Sep 1;39(33):3021–104.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 In-ternational Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334–57. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
Brown MA, Mangos G, Davis G, Homer C. The natural history of white coat hyperten-sion during pregnancy. BJOG Int J Obstet Gynaecol. 2005;112(5):601–6. DOI: https://doi.org/10.1111/j.1471-0528.2004.00516.x
Tucker KL, Bankhead C, Hodgkinson J, Roberts N, Stevens R, Heneghan C, et al. How Do Home and Clinic Blood Pressure Readings Compare in Pregnancy? Hypertension. 2018 Sep;72(3):686–94. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.10917
Johnson S, Liu B, Kalafat E, Thilaganathan B, Khalil A. Maternal and Perinatal Out-comes of White Coat Hypertension During Pregnancy: A Systematic Review and Meta-Analysis. Hypertens Dallas Tex 1979. 2020 Jul;76(1):157–66. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.14627
Verlohren S, Dröge LA. The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. Am J Obstet Gynecol. 2022 Feb 1;226(2, Supple-ment):S1048–58. DOI: https://doi.org/10.1016/j.ajog.2020.09.046
Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016 Jan 7;374(1):13–22. DOI: https://doi.org/10.1056/NEJMoa1414838
Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. The Lancet. 2019 May 4;393(10183):1807–18. DOI: https://doi.org/10.1016/S0140-6736(18)33212-4
DSOG. Acetylsalicylsyre i graviditeten. 2021 p. 1–58.
Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, et al. Pravas-tatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation. 2021 Aug 31;144(9):670–9. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.053963
Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, et al. Risk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis. Diabet Med. 2018 Feb;35(2):160–72. DOI: https://doi.org/10.1111/dme.13523
Hyppönen E, Cavadino A, Williams D, Fraser A, Vereczkey A, Fraser WD, et al. Vita-min D and Pre-Eclampsia: Original Data, Systematic Review and Meta-Analysis. Ann Nutr Metab. 2013;63(4):331–40. DOI: https://doi.org/10.1159/000358338
Woo Kinshella M, Sarr C, Sandhu A, Bone JN, Vidler M, Moore SE, et al. Calcium for pre‐eclampsia prevention: A systematic review and network meta‐analysis to guide personalised antenatal care. BJOG Int J Obstet Gynaecol. 2022 Oct;129(11):1833–43. DOI: https://doi.org/10.1111/1471-0528.17222
Li S, Yang Q, Niu S, Liu Y. Effectiveness of Remote Fetal Monitoring on Maternal-Fetal Outcomes: Systematic Review and Meta-Analysis. JMIR MHealth UHealth. 2023 Feb 22;11:e41508. DOI: https://doi.org/10.2196/41508
Zizzo AR, Hvidman L, Salvig JD, Holst L, Kyng M, Petersen OB. Home management by remote self‐monitoring in intermediate‐ and high‐risk pregnancies: A retrospective study of 400 consecutive women. Acta Obstet Gynecol Scand. 2022 Jan;101(1):135–44. DOI: https://doi.org/10.1111/aogs.14294
Bekker MN, Koster MPH, Keusters WR, Ganzevoort W, De Haan-Jebbink JM, Deurloo KL, et al. Home telemonitoring versus hospital care in complicated pregnancies in the Nether-lands: a randomised, controlled non-inferiority trial (HoTeL). Lancet Digit Health. 2023 Mar;5(3):e116–24. DOI: https://doi.org/10.1016/S2589-7500(22)00231-X
Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. The Lancet. 2009 Sep;374(9694):979–88. DOI: https://doi.org/10.1016/S0140-6736(09)60736-4
Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022 May 12;386(19):1781–92.
NICE. Hypertension in pregnancy: Diagnosis and Management (NG133) 2019 [Inter-net]. 2019. Available from: www.nice.org.uk/guidance/ng133
Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Pregnancy and Childbirth Group, editor. Cochrane Database Syst Rev [Internet]. 2018 Oct 1 [cited 2024 Jun 5];2018(10). Available from: http://doi.wiley.com/10.1002/14651858.CD002252.pub4 DOI: https://doi.org/10.1002/14651858.CD002252.pub4
SFOG. Hypertension i graviditeten. 2022.
The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with ec-lampsia? Evidence from the Collaborative Eclampsia Trial. The Lancet. 1995 Jun;345(8963):1455–63. DOI: https://doi.org/10.1016/S0140-6736(95)91034-4
Hatab MR, Zeeman GG, Twickler DM. The effect of magnesium sulfate on large cer-ebral artery blood flow in preeclampsia. J Matern Fetal Neonatal Med. 2005 Mar 1;17(3):187–92. DOI: https://doi.org/10.1080/14767050500073050
Belfort MA, Saade GR, Moise KJ. The effect of magnesium sulfate on maternal reti-nal blood flow in preeclampsia: A randomized placebo-controlled study. Am J Obstet Gynecol. 1992 Dec;167(6):1548–53. DOI: https://doi.org/10.1016/0002-9378(92)91737-U
Giorgione V, Jansen G, Kitt J, Ghossein-Doha C, Leeson P, Thilaganathan B. Peripar-tum and Long-Term Maternal Cardiovascular Health After Preeclampsia. Hypertension. 2023 Feb;80(2):231–41. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.122.18730
Cairns AE, Tucker KL, Leeson P, Mackillop LH, Santos M, Velardo C, et al. Self-Management of Postnatal Hypertension: The SNAP-HT Trial. Hypertension. 2018 Aug;72(2):425–32. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.10911
Premkumar A, Ayala NK, Miller CH, Grobman WA, Miller ES. Postpartum NSAID Use and Adverse Outcomes among Women with Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-analysis. Am J Perinatol. 2021 Jan;38(01):001–9. DOI: https://doi.org/10.1055/s-0040-1713180